Catalent Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Catalent wird ein jährliches Gewinn- und Umsatzwachstum von 98.4% bzw. 6.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 104.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9% betragen.

Wichtige Informationen

98.4%

Wachstumsrate der Gewinne

104.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.6%
Wachstumsrate der Einnahmen	6.8%
Zukünftige Eigenkapitalrendite	9.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:CTLT * - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	5,380	361	N/A	N/A	1
6/30/2026	5,056	152	N/A	756	8
6/30/2025	4,692	41	39	482	9
6/30/2024	4,381	-1,043	-59	268	N/A
3/31/2024	4,135	-1,176	-123	250	N/A
12/31/2023	4,098	-1,302	-263	174	N/A
9/30/2023	4,223	-1,015	-235	276	N/A
6/30/2023	4,263	-256	-322	254	N/A
3/31/2023	4,495	21	-563	127	N/A
12/31/2022	4,731	389	-371	329	N/A
9/30/2022	4,799	399	-471	184	N/A
6/30/2022	4,802	483	-221	439	N/A
3/31/2022	4,703	485	-110	504	N/A
12/31/2021	4,483	561	-183	441	N/A
9/30/2021	4,177	544	-244	446	N/A
6/30/2021	3,998	529	-253	433	N/A
3/31/2021	3,757	494	-188	471	N/A
12/31/2020	3,465	289	-135	518	N/A
9/30/2020	3,275	250	22	565	N/A
6/30/2020	3,094	173	-26	440	N/A
3/31/2020	2,872	104	-37	356	N/A
12/31/2019	2,729	124	20	309	N/A
9/30/2019	2,631	138	-22	232	N/A
6/30/2019	2,518	132	30	248	N/A
3/31/2019	2,478	149	75	263	N/A
12/31/2018	2,488	136	108	283	N/A
9/30/2018	2,471	65	160	332	N/A
6/30/2018	2,463	84	198	375	N/A
3/31/2018	2,395	63	N/A	371	N/A
12/31/2017	2,300	70	N/A	380	N/A
9/30/2017	2,177	109	N/A	335	N/A
6/30/2017	2,075	110	N/A	300	N/A
3/31/2017	1,991	106	N/A	233	N/A
12/31/2016	1,896	91	N/A	180	N/A
9/30/2016	1,867	104	N/A	159	N/A
6/30/2016	1,848	112	N/A	155	N/A
3/31/2016	1,826	207	N/A	199	N/A
12/31/2015	1,835	228	N/A	243	N/A
9/30/2015	1,836	244	N/A	257	N/A
6/30/2015	1,831	212	N/A	172	N/A
3/31/2015	1,840	86	N/A	180	N/A
12/31/2014	1,847	62	N/A	138	N/A
9/30/2014	1,832	-3	N/A	113	N/A
6/30/2014	1,828	19	N/A	178	N/A
3/31/2014	1,813	2	N/A	148	N/A
12/31/2013	1,807	-20	N/A	152	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CTLT * wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (7.9%).

Ertrag vs. Markt: CTLT * wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CTLT * wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CTLT *Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt MX (7.2% pro Jahr).

Hohe Wachstumseinnahmen: CTLT *Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CTLT *Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9%).

Catalent Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Insider recently sold Mex$4.4m worth of stock

President recently sold Mex$10.0m worth of stock

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

President recently sold Mex$1.6m worth of stock

Insufficient new directors

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold Mex$1.3m worth of stock

Investor sentiment deteriorates as stock falls 36%

Investor sentiment improves as stock rises 50%

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Danaher Reportedly Expresses Takeover Interest in Catalent

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Insider recently sold Mex$796k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold Mex$3.2m worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Now 22% undervalued

Investor sentiment deteriorated over the past week

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Investor sentiment deteriorated over the past week

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Executive Chair of the Board recently sold Mex$80m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Catalent, Inc. Announces Board Changes

Insider recently sold Mex$251k worth of stock

Insider recently sold Mex$251k worth of stock

Insufficient new directors

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022